[TCT2008]亚洲注册研究：Cypher和Xience支架有更低的再狭窄率

发布于:2008-10-16 18:22

高立建，博士，心内科主治医师，从事血管内超声研究、冠心病诊治及科研工作。

Dr Lijian-Gao, medical doctor, a doctor of cardiovascular department of Fu Wai Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), who engaged in the diagnosis and treatment of CHD and Basic research related to CHD as well as the Clinical Application Study of Intravascular ultrasound .

亚洲注册研究：Cypher和Xience支架有更低的再狭窄率

Cypher, Xience Showed Less Restenosis at One Year in Asian Registry

（阜外心血管病医院高立建编译）

根据釜山注册研究结果：Cypher支架 (强生公司), Taxus支架 (波士顿科技公司), Endeavor支架 (美敦力公司), Genous支架 (业聚公司), 和Xience支架 (雅培血管部)几种支架均能明显降低引起胸痛症状或诱发缺血的支配动脉阻塞的再狭窄率和TLR。

Sunao Nakamura是日本熊本大学的新东京循环研究组成员和新东京医院心内科医生，他讲道：几种支架中Cypher支架和Xience支架12个月随访的再狭窄率最低（见图）

这两种支架与其他三种支架(Taxus支架为9.3%; Endeavor支架为12.3%; Genous支架为12.9%)相比TVR也比较低(Cypher支架为 5.8%; Xience支架为7.1%)，Cypher支架组TLR最低(4.4%)，其次为Xience支架组(4.8%)。

总体而言，12个月总的主要心脏不良事件Cypher支架组为8.7%，Taxus支架组为10.3%，Endeavor支架组为15.6%，Genous支架组为16.1%和Xience支架组为7.1%。除了Xience支架组之外，其他组均报道了MI发生率(Cypher支架组为0.8%; Taxus支架组为0.8%; Endeavor支架组为 1.3%; Genous支架组为0.5%)。12个月随访Xience或Genous支架组没有1例患者发生支架内血栓，而Cypher支架组、Taxus支架组、Endeavor支架组和Genous支架组分别为1%，1%，1.3%和0.5%。

釜山多中心注册研究共入选了1082例应用上述五种支架进行治疗的CTO患者。

（来源：www.tctmd.com）

Cypher, Xience Showed Less Restenosis at One Year in Asian Registry

By TCT Daily Staff

Cypher (Cordis Corporation), Taxus (Boston Scientific), Endeavor (Medtronic), Genous (OrbusNeich), and Xience (Abbott Vascular) dramatically decreased the rate of restenosis and TLR in patients symptomatic for chest pain or presenting with inducible ischemia in the area supplied by the occluded artery, according to results of an Asian registry.

Sunao Nakamura, MD, PhD, of the New Tokyo Circulation Research Group and New Tokyo Hospital and the department of cardiology at Kumamoto University, Japan, said Cypher and Xience had the best restenosis rates at 12-month follow-up (see Figure).

The two stents also had lower TVR rates (Cypher, 5.8%; Xience, 7.1%) compared with the other three stents (Taxus, 9.3%; Endeavor, 12.3%; Genous, 12.9%). TLR rates were lowest in the Cypher group (4.4%) and the Xience group (4.8%).

Overall, major cardiac event rates at 12 months were 8.7% for Cypher, 10.3% for Taxus, 15.6% for Endeavor, 16.1% for Genous and 7.1% for Xience. All the groups except the Xience group had reported rates of MI (Cypher, 0.8%; Taxus, 0.8%; Endeavor, 1.3%; Genous 0.5%).

None of the patients with either a Xience or Genous stent experienced thrombosis at 12 months, compared with 1% of patients in both the Cypher and Taxus groups and 0.6% of patients in the Endeavor group.

The multicenter Asian registry included 1,082 patients with CTO lesions treated with any of the five stents.

Disclosures:

Dr. Nakamura reports no relevant conflicts of interest.

（source：www.tctmd.com）

来源：医心网

上一篇：重磅｜中国自主研发心血管OCT系统正式上市助力PCI精准治疗

下一篇：[TCT2008]COOL RCN研究显示未明显地降低对比剂肾病

相关文章: